

FACULTY POSITION, ADME/TOXICOLOGY and DIVISION HEAD, CDRD

Faculty of Pharmaceutical Sciences,
The University of British Columbia and
Centre for Drug Research and Development

Applications are invited for the full-time, tenured position of Professor, Faculty of Pharmaceutical Sciences, The University of B.C. The successful candidate will contribute to excellence in teaching and training for the Faculty's undergraduate and graduate programs and will serve as Division Head, Drug Evaluation, Centre for Drug Research and Development (CDRD). It is expected the selected candidate will develop an active, extramurally-funded research program and establish a strong research group in drug metabolism/toxicology that contributes both to the Faculty and to the CDRD (<http://www.cdrd.ca>).

Applicants must have a PhD degree and a minimum of 7-12 years of independent research experience in drug metabolism/toxicology (in vitro, in vivo) at a senior level within academic and/or industrial settings. To be considered for this dual role, individuals must have: demonstrated their ability to conduct and direct translational research to develop new drug technologies from academic discoveries; achieved wide recognition in the ADME/toxicology field; maintained a strong publications record; been engaged in intellectual property filings; and demonstrated teaching/learning excellence.



The closing date for applications is **November 15, 2007**. UBC hires on the basis of merit and is committed to employment equity. We encourage all qualified persons to apply, however, Canadian citizens and permanent residents will be given priority. For full details of the advertisement & application process, please refer to the website link: http://www.pharmacy.ubc.ca/career_opportunities/faculty.html



Recruiters: Don't miss this important message!

TO: Recruiters wanting to promote open positions, fellowship opportunities, programs, or conference announcements.

TIME: Now

MESSAGE: The publications of the **American Society for Pharmacology and Experimental Therapeutics (ASPET)** are a perfect way to advertise to basic and clinical researchers in all disciplines of pharmacology. **And now the full issues of all the ASPET publications are made available online in a pdf format.** So your ad gets additional exposure online for free. Run a line ad in ***Molecular Intervention's Professional Opportunities*** section for \$10 per line and receive a FREE job posting on the ASPET website for 8 weeks.

NOTE: Line ad is only available in ***Molecular Interventions***. Quarter, half, and full page ad sizes are available in all of the ASPET publications. Issues close 35 working days preceding the issue month.

ACTION REQUESTED: Email your ad to adnet@faseb.org for a quote.

Contact FASEB AdNet at 301-634-7791.
View full media kit at www.faseb.org/adnet.

THE TACONIC ADVANTAGE

ADME-Tox

Another Taconic breakthrough:
The first and only portfolio of commercially
available, fully licensed transgenic
ADME-Tox mouse models.

Includes:

Mrp2

Oct1/2

Bcrp

Mdr1a

Mdr1a/b

Mdr1a/b-Bcrp

Coming soon:

PXR

and

HRN™

Available exclusively
from Taconic.



Call today to put the Taconic
Advantage to work for you.

Taconic

Smart Solutions To Improve Human Health

1.866.382.5294

www.taconic.com/adme_dmd

Recruiters: Don't miss this important message!

TO: Recruiters wanting to promote open positions, fellowship opportunities, programs, or conference announcements.

TIME: Now

MESSAGE: The publications of the **American Society for Pharmacology and Experimental Therapeutics (ASPET)** are a perfect way to advertise to basic and clinical researchers in all disciplines of pharmacology. **And now the full issues of all the ASPET publications are made available online in a pdf format.** So your ad gets additional exposure online for free. Run a line ad in ***Molecular Intervention's Professional Opportunities***' section for \$10 per line and receive a FREE job posting on the ASPET website for 8 weeks.

NOTE: Line ad is only available in ***Molecular Interventions***. Quarter, half, and full page ad sizes are available in all of the ASPET publications. Issues close 35 working days preceding the issue month.

ACTION REQUESTED: Email your ad to adnet@faseb.org for a quote.

Contact FASEB AdNet at 301-634-7791 for more information.

View full media kit at www.faseb.org/adnet.

Statement of Ownership, Management, and Circulation (All Periodicals Publications Except Requester Publications)

1. Publication Title: Drug Metabolism and Disposition. 2. Publication Number 0090-9556. 3. Filing Date: September 5, 2007. 4. Issue Frequency: monthly. 5. Number of Issues Published Annually: 12. 6. Annual Subscription Price: \$353.00. 7. Complete Mailing Address of Known Office of Publication: American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, MD 20814-3995. Contact Person: Richard Dodenhoff. Telephone: 301-634-7997. 8. Complete Mailing Address of Headquarters or General Business Office of Publisher: American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, MD 20814-3995. 9. Full Names and Complete Mailing Addresses of Publisher, Editor, and Managing Editor: Publisher: American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, MD 20814-3995. Editor: Dr. Eric F. Johnson, Scripps Research Institute, Department of Molecular & Experimental Medicine, MEM-255, 10550 N Torrey Pines Rd, La Jolla, CA 92037. Managing Editor: Jill Filler, American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, MD 20814-3995. 10. Owner: American Soc. for Pharmacology & Experimental Therapeutics, 9650 Rockville Pike, Bethesda, MD 20814-3995. 11. Known Bondholders, Mortgagees, and Other Security Holders Owning or Holding 1 Percent or More of Total Amount of Bonds, Mortgages, or Other Securities: None. 12. Tax Status: The purpose, function, and nonprofit status of this organization and the exempt status for federal income tax purposes: Has Not Changed During Preceding 12 Months. 13. Publication Title: Drug Metabolism and Disposition. 14. Issue Date for Circulation Data: September 2007. 15. Extent and Nature of Circulation: Average No. Copies Each Issue During Preceding 12 Months: a. Total Number of Copies: 734. b. Paid Circulation: (1) Mailed Outside-County Paid Subscriptions Stated on PS Form 3541: 373; (2) Mailed In-County Paid Subscriptions Stated on PS Form 3541: 0; (3) Paid Distribution Outside the Mails Including Sales Through Dealers and Carriers, Street Vendors, Counter Sales, and Other Paid Distribution Outside USPS®: 158; (4) Paid Distribution by Other Classes of Mail Through the USPS: 0. c. Total Paid Distribution: d. Free or Nominal Rate Distribution: (1) Free or Nominal Rate Outside-County Copies Included on PS Form 3541: 40; (2) Free or Nominal Rate In-County Copies Included on PS Form 3541: 0; (3) Free or Nominal Rate Copies Mailed at Other Classes Through the USPS: 0; (4) Free or Nominal Rate Distribution Outside the Mail: 7. e. Total Free or Nominal Rate Distribution: 47. f. Total Distribution: 578. g. Copies not Distributed: 156. h. Total: 734. i. Percent Paid: 91.8685. No. Copies of Single Issue Published Nearest to Filing Date: a. Total Number of Copies: 660. b. Paid Circulation: (1) Mailed Outside-County Paid Subscriptions Stated on PS Form 3541: 362; (2) Mailed In-County Paid Subscriptions Stated on PS Form 3541: 0; (3) Paid Distribution Outside the Mails Including Sales Through Dealers and Carriers, Street Vendors, Counter Sales, and Other Paid Distribution Outside USPS®: 156; (4) Paid Distribution by Other Classes of Mail Through the USPS: 0. c. Total Paid Distribution: 518. d. Free or Nominal Rate Distribution: (1) Free or Nominal Rate Outside-County Copies Included on PS Form 3541: 36; (2) Free or Nominal Rate In-County Copies Included on PS Form 3541: 0; (3) Free or Nominal Rate Copies Mailed at Other Classes Through the USPS: 0; (4) Free or Nominal Rate Distribution Outside the Mail: 7. e. Total Free or Nominal Rate Distribution: 43. f. Total Distribution: 561. g. Copies not Distributed: 99. h. Total: 660. i. Percent Paid: 92.3351. 16. Publication of Statement of Ownership: If the publication is a general publication, publication of this statement is required. Will be printed in the October 2007 issue of this publication. 17. Signature and Title of Editor, Publisher, Business Manager, or Owner: Richard C. Dodenhoff II, Journals Director. September 5, 2007. I certify that all information furnished on this form is true and complete. I understand that anyone who furnishes false or misleading information on this form or who omits material or information requested on the form may be subject to criminal sanctions (including fines and imprisonment) and/or civil sanctions (including civil penalties).

PLAN ON ATTENDING

The American Society for Pharmacology and Experimental Therapeutics

Centennial Celebration at Experimental Biology 2008

San Diego, CA, April 5 - 9

FEATURING...

SPECIAL CENTENNIAL SYMPOSIA:

P450s: Structure, Function, In Silico Predictions

Spkrs: Anthony Lu, Paul Ortiz de Montellano, William Atkins, Eric Johnson, Lovisa Afzelius

Development of Inhibitors of the Soluble Epoxide Hydrolase as a Novel Treatment for Hypertension, Vascular Inflammation and End Organ Damage

Spkrs: Michael Arand, Heather Webb, Bruce Hammock, William Campbell, Darryl Zeldin, John Imig

New Experimental Approaches to the Treatment of Schizophrenia: Moving Beyond Monoamine Antagonists

Spkrs: Carol Tamminga, Darryle Schoepp, Jeffrey Conn, Craig Lindsley

The G-Whizards of GPCR/G-Protein Signaling

Spkrs: Alfred Gilman, Lee Limbird, Robert Lefkowitz, Heidi Hamm

Chance Favors the Prepared Mind: A Nobel Perspective

Spkrs: Alfred Gilman, Louis Ignarro, Ferid Murad

The Obesity Epidemic: Pharmacological Challenges

Spkrs: Matthias Tschop, Francis Kuhajda, Stephen Bloom, Xavier Pi-Sunyer, D. Scott Weigle

Drug Discovery Paradigms: Past, Present, and Future

Spkrs: S.J. Enna, Graeme Milligan, Robert Ruffolo, Brian Zambrowicz

New Concepts in an Old System: Renin-Angiotensin System Blockade as Therapy for General Cardiovascular Disease

Pharmacotherapies for Drug Abuse: The Cocaine Challenge

Spkrs: Kenneth Silverman, Jonathan Katz, James Woods, William Woolverton, Maxine Stitzer

ABC Transporters: From Drug Resistance to Drug Response

Spkrs: Erin Schuetz, Alfred Schinkel, Susan Bates, Susan Cole, Richard Kim

Julius Axelrod Symposium:

Celebrating a Pioneer Pharmacologist and His Legacy: Creating New Drugs by Revealing Mechanisms of Drug Action in Fundamental Biological Processes

Spkrs: Susan Amara, Marc Caron, Solomon Snyder, Richard Weinshilboum

PARTIES:

Opening Ceremony at EB 2008

featuring music, food, and excitement

ASPET Birthday Party

held at a special attraction in San Diego

ASPET Student Fiesta

featuring music, food, drinks, and dancing

Nobel Laureate Reception For Students & Postdocs

honoring ASPET's Nobel Laureates

COMMEMORATIVE GIFTS:

**Ten Decades of Pharmacology Poster
ASPET Centennial Publication Collection**

ASPET Lapel Pins

Luggage Tags

T-shirts

Plus much more!



KEEP UP-TO-DATE WITH CENTENNIAL NEWS
VISIT US AT

www.aspet.org



Working for a healthier world™

Pharmacokinetics, Dynamics, and Metabolism



When do discoveries become miracles?

Imagine what you can achieve in the largest drug metabolism and pharmacokinetics group in the world. Imagine playing a critical role in discovery and development. Imagine translating leading research into life-saving medicines.

At Pfizer Global Research & Development (PGRD), we're not content waiting to witness the evolution of our industry. Instead, we're driven by science, building on our current successes and capabilities, playing a critical role in developing the most compelling story of scientific discoveries.

Our research pipeline spans many therapeutic areas and to date we've brought to market such outstanding medicines as Lipitor, Chantix, Sutent, Lyrica, Exubera, and Viagra. And in the future we'll bring many more therapies and cures to the marketplace, making the world a healthier place for all.

Pfizer Pharmacokinetics, Dynamics, and Metabolism (PDM) is the largest drug metabolism and pharmacokinetics group in the world. With over \$100 MM per year invested in the latest research and technology, PDM plays a critical part in both drug discovery and drug development - its primary role being the characterization of the effects of the body on potential drug entities ranging from chemically synthesized small molecules to biologically derived macromolecules. Core competencies include: in vitro and in vivo ADME research (transporters and metabolism), biologics research, bioanalytical science and automation, PK/PD modeling and biomarkers, and in silico and computational modeling.

But there is much more work to be done and we can't do it alone. That's why we're always seeking those who share our belief that science can improve our world, that by working together we can bring exciting new therapies to patients on a global scale and forever change the way we improve the health and well-being of all people.

Now you can be a vital member of a research and development company unlike any other, Pfizer Global Research & Development. Join us and use your talents to turn discoveries into miracles.

To learn more about our people, our products, and our plans for the future, visit www.pfizerdrugmetabolism.com

We're proud to be an equal opportunity employer and welcome applications from people with different experiences, backgrounds and ethnic origins.